Sarepta Therapeutics Inc. tried using company financial problems to push FDA to complete the final stages of the review of the Duchenne muscular dystrophy drug Exondys 51 while also telling investors there was enough operating capital to continue for a year.
The move did not work because FDA's approval was delayed several months after officials appealed the final decision made by Center for Drug Evaluation and Research Director Janet Woodcock